This also translated into differential surface expression of potential drug targets, such as PD-L1 (CD274) and CTLA4 (CD152) (Fig. 4h and Extended Data Fig. 7f), suggesting that the myeloid differentiation program of the AML might be essential in the treatment choice of targeted immune therapies. This evidence concerns the gene CD274 and acute myeloid leukemia.